Core Viewpoint - The 5-year follow-up results of Moderna's personalized mRNA cancer vaccine V940 in high-risk melanoma support the vaccine's mechanism to provide durable immune responses, providing a stronger clinical basis for subsequent Phase III and registration advancements [1][2]. Group 1: Clinical Results - On January 21, 2026, Moderna and Merck announced the 5-year follow-up results of the Phase IIb study of V940 (mRNA-4157) combined with Keytruda for adjuvant treatment of high-risk melanoma, demonstrating sustained efficacy over a long period [2]. - The KEYNOTE-942 study results indicate that the combination of V940 and Keytruda reduces the risk of recurrence or death in high-risk melanoma patients by 49%, maintaining this efficacy from 2 years (44%) to 3 years (49%) and remaining at 49% at the 5-year follow-up [2]. - No new safety signals were observed during the study, indicating a favorable safety profile for the treatment [2]. Group 2: Development Progress - V940 is advancing ahead of similar projects, with 8 ongoing Phase II/III clinical studies covering various solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma [2]. - The Phase III clinical trial for melanoma has completed enrollment and is expected to yield critical data in 2026; the project has also received FDA breakthrough therapy designation, providing regulatory support for future registration applications [2]. Group 3: Technological Validation - The data readout provides evidence for the transition of mRNA tumor vaccines from concept validation to pathway validation, with mRNA-4157 being a personalized neoantigen therapy capable of encoding up to 34 neoantigens [3]. - The therapy activates T-cell responses with immune memory characteristics and complements PD-1 inhibitors, showing that efficacy does not significantly diminish over time, distinguishing it from previous unsuccessful attempts at tumor vaccines [3].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [4][10][13]. Core Insights - The report continues to recommend the innovative pharmaceutical and medical device industry chain, including a list of A-share and H-share stocks with an "Overweight" rating [2][10][13]. - In January 2026, the pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index rising by 3.8% while the SW Pharmaceutical and Biological Index increased by 3.1% [15][24]. - The report highlights that the medical services, chemical raw materials, and medical devices sub-sectors performed relatively well, with increases of 8.8%, 5.6%, and 5.3% respectively [19][24]. - The report notes that the A-share pharmaceutical sector's premium level is currently at a normal level, with a relative premium rate of 61.1% as of the end of January 2026 [21][26]. Summary by Sections 1. Continued Recommendation for Innovative Pharmaceutical and Medical Device Industry - The report maintains an "Overweight" rating for the following A-share stocks: Hengrui Medicine, Kelun Pharmaceutical, Xinlitai, BeiGene, Teru Biopharma, Jingxin Pharmaceutical, Yifang Biopharma, WuXi AppTec, Kailai Pharmaceutical, Tigermed, Lepu Medical, United Imaging, Microelectrophysiology, and Tongce Medical, and includes these stocks in the February 2026 monthly portfolio [10][12][13]. 2. January 2026 Pharmaceutical Sector Performance - The report states that the pharmaceutical sector underperformed the market in January 2026, with the SW Pharmaceutical and Biological Index ranking 18th among the Shenwan first-level industries [15][16][24]. 3. January 2026 Performance of Hong Kong and US Pharmaceutical Sectors - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare Index rising by 8.6% and the biotechnology sector by 8.5%, compared to a 6.9% increase in the Hang Seng Index [24]. - Conversely, the US pharmaceutical sector underperformed, with the S&P Healthcare Select Sector Index declining by 0.3% while the S&P 500 rose by 1.4% [24].

Investment Rating - The report assigns an "Overweight" rating for the industry, indicating an expected performance that exceeds the Shanghai and Shenzhen 300 Index by more than 15% [4][10]. Core Insights - The report highlights the five-year follow-up results of Moderna's personalized mRNA cancer vaccine V940 in high-risk melanoma, supporting the vaccine's mechanism to provide durable immune responses, which strengthens the clinical basis for subsequent Phase III and registration advancements [2][5]. - The KEYNOTE-942 study results show that the combination of V940 and Keytruda reduces the risk of recurrence or death in high-risk melanoma patients by 49%, with efficacy maintaining from 44% at the two-year follow-up to 49% at the three-year and five-year follow-ups, without new safety signals being reported [5]. - V940 is advancing ahead of similar projects, with eight ongoing Phase II/III clinical studies covering various solid tumors, including melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma. The Phase III trial for melanoma has completed enrollment and is expected to yield critical data in 2026, with the project also receiving FDA breakthrough therapy designation [5]. Summary by Sections - **Investment Highlights**: The report emphasizes the sustained efficacy of V940 in inducing durable immune responses, differentiating it from previous unsuccessful cancer vaccine attempts, and providing long-term clinical data support for mRNA tumor vaccine technology [5]. - **Clinical Data**: The report details that V940 can encode up to 34 new antigens, activating T-cell responses with immune memory characteristics, complementing PD-1 inhibitors [5].

Core Insights - Moderna (MRNA.US) shares rose 5.6% in pre-market trading, reaching $52.6, following a significant increase of nearly 16% the previous day [1] - Merck and Moderna jointly disclosed phase II clinical trial data for the mRNA cancer vaccine mRNA-4157 in combination with Keytruda, showing a 49% reduction in the risk of recurrence or death for high-risk stage III/IV melanoma patients compared to Keytruda monotherapy [1] - The data supports the scientific hypothesis that mRNA cancer vaccines can induce a durable immune response [1]

Core Insights - The collaboration between Merck and Moderna on the mRNA cancer vaccine mRNA-4157 has shown promising results, significantly reducing the risk of recurrence or death by 49% in high-risk melanoma patients when combined with the PD-1 inhibitor Keytruda [1][2] - The mRNA-4157 vaccine utilizes a personalized neoantigen therapy mechanism, which designs synthetic mRNA encoding up to 34 neoantigens based on the unique mutations in a patient's tumor DNA [2] - The market potential for mRNA cancer vaccines is substantial, with projections indicating that they could become a new class of cancer immunotherapy, combining accessibility and personalization [4] Company Developments - Moderna plans to increase investment in the oncology sector, with the Phase III clinical trial for mRNA-4157 fully enrolled and expanding its indications beyond melanoma [2] - EVM16, a personalized cancer vaccine developed by the domestic company, has entered human trials, marking a significant milestone in the application of mRNA technology combined with AI for neoantigen selection [3] - The clinical data from EVM16 is expected to be released in the next 6-12 months, with the company aiming to initiate Phase Ib studies thereafter [3] Industry Trends - The success of mRNA-4157 highlights the unmet needs in cancer treatment, with the industry recognizing the potential of mRNA cancer vaccines to address these gaps [4] - The competitive landscape for personalized cancer vaccines is evolving, with domestic companies like EVM16 accelerating their development efforts in response to the advancements made by global players [4]

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) announced that its wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injectable YKYY031, a universal mRNA tumor vaccine intended for the treatment of advanced solid tumors [2]. Group 1 - Yuyuan Pharmaceutical's subsidiary has obtained a clinical trial approval for YKYY031 [2] - YKYY031 is designed as a universal mRNA vaccine targeting advanced solid tumors [2]

Core Viewpoint - YKYY031, a novel mRNA tumor vaccine developed by the company, has received approval from the National Medical Products Administration (NMPA) for clinical trials targeting advanced solid tumors [2][3] Group 1: Product Development - YKYY031 is designed as a general mRNA tumor vaccine for the treatment of advanced solid tumors, utilizing a proprietary cationic lipid-based lipid nanoparticle (LNP) delivery system that offers high delivery efficiency and good safety [2] - The vaccine contains mRNA sequences encoding multiple tumor-associated antigens (TAA) and tumor-specific antigens (TSA), which can induce specific cytotoxic T cell responses to inhibit tumor cell growth [2] Group 2: Intellectual Property - The core sequence and delivery system of YKYY031 have been granted invention patent authorization by the National Intellectual Property Administration, and international patent applications have been completed, granting the company global exclusive rights [2] Group 3: Preclinical Research - Preclinical studies have demonstrated significant efficacy and good safety for YKYY031, showing the ability to induce strong and lasting tumor antigen-specific T cell immune responses and clear anti-tumor activity under various dosing regimens [3] - The combination of YKYY031 with anti-PD-1 antibodies has been shown to further enhance therapeutic efficacy [3] Group 4: Stability and Logistics - The product employs advanced LNP freeze-drying technology, which eliminates the dependence on ultra-low temperature cold chain logistics, significantly reducing transportation and storage costs while improving accessibility [3]

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) has received approval from the National Medical Products Administration (NMPA) for its clinical trial of the injectable YKYY031, a generic mRNA tumor vaccine intended for the treatment of advanced solid tumors [1] Group 1 - The clinical trial approval is granted to Yuyuan Pharmaceutical's wholly-owned subsidiary, Beijing Yuyuan Kete Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. [1] - YKYY031 is designed to treat advanced solid tumors and utilizes a novel cationic lipid YK-009-based lipid nanoparticle (LNP) delivery system, which is characterized by high delivery efficiency and good safety [1]

Core Viewpoint - YKYY031, a novel mRNA tumor vaccine developed by the company, has received approval from the National Medical Products Administration (NMPA) for clinical trials targeting advanced solid tumors [1][2] Group 1: Product Development - YKYY031 is designed to treat advanced solid tumors using a lipid nanoparticle (LNP) delivery system based on the company's proprietary cationic lipid YK-009, which offers high delivery efficiency and good safety [1] - The vaccine contains mRNA sequences that encode multiple tumor-associated antigens (TAA) and tumor-specific antigens (TSA), aiming to induce specific cytotoxic T cell responses to inhibit tumor growth [1] Group 2: Clinical Research and Efficacy - Preclinical studies have demonstrated significant efficacy and good safety for YKYY031, showing the ability to induce durable tumor antigen-specific T cell immune responses and clear anti-tumor activity under various dosing regimens [2] - The combination of YKYY031 with anti-PD-1 antibodies has been shown to further enhance therapeutic efficacy [2] Group 3: Safety and Stability - Toxicological studies indicate that YKYY031 has a good safety profile and a broad therapeutic window, providing a solid foundation for clinical application [2] - The advanced LNP lyophilization process used for YKYY031 overcomes the dependency on ultra-low temperature cold chain logistics, significantly reducing transportation and storage costs while improving accessibility [2]

Core Viewpoint - The announcement indicates that Yuyuan Pharmaceutical's wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injectable YKYY031, a generic mRNA tumor vaccine intended for the treatment of advanced solid tumors [1] Group 1 - Yuyuan Pharmaceutical's subsidiary has obtained a clinical trial approval notice for YKYY031 [1] - YKYY031 is designed as a generic mRNA tumor vaccine [1] - The vaccine is aimed at treating advanced solid tumors [1]